In 2009, Johnston et al [2] reported lapatinib to improve therapeutic efficacy of aromatase inhibition in a small subgroup of patients with poor prognosis ER+ tumours harbouring normal HER2 gene copy numbers. The gene discussed is ESR1; the disease is neoplasm.